| Literature DB >> 29414500 |
Luis Cuitláhuac Becerra-Pedraza1, Luis Enrique Jiménez-Martínez2, Iran Peña-Morfin3, Rogelio Nava-Esquivel4, Juan Alfredo Villegas-Martínez2.
Abstract
INTRODUCTION: Priapism is an uncommon sign and sometimes considered a diagnosis challenge into systemic disease; this is defined as ≥4 h continuous penile erection, without sexual stimulation. We state that this work has been reported in line with the SCARE criteria PRESENTATION OF CASE: A Mexican 52-year-old man was brought to the emergency room with priapism of six days of evolution. His medical history reported fatigue and waxy pallor had begun a month ago, the rest of interrogation was unremarked. Hyperleukocitosis (>250,000 cells/ml) was documented on his preoperative evaluation, the initial step was hematology consultation due to malignance suspicion, followed by corpora cavernosa drainage-irrigation and surgery penis shunts. After of procedure, we realized bone marrow aspiration, kariotype and cytogenetic analysis, histopathological and moleculars assay reported myeloid hyperplasia compatible with acute phase CML and Philadelphia translocation t(9:22) (q34;q11.2) with P210 BCR-ABL1 fusion transcriber, patient was discharged with dasatinib for maintenance phase. Actually, he has a satisfactory evolution without relapses. DISCUSSION: The majority of reported cases shows the individual importance of hematological diseases in priapism as it is shown in the analysis of the literature of 10 years (2006-2016) that we made. It is imperative to consider the type of priapism, and the genetic and demographic patient aspects due to the early and correct approach improves the short and long term outcome of the hematological patients.Entities:
Keywords: Case report; Chronic myeloid leukemia; Leukemic priapism; Malignant priapism; Priapism
Year: 2018 PMID: 29414500 PMCID: PMC5907689 DOI: 10.1016/j.ijscr.2017.12.038
Source DB: PubMed Journal: Int J Surg Case Rep ISSN: 2210-2612
Fig. 1A) Post-operative surgical image shows the system corpora cavernosa drainage-irrigation. B) Kariotype image display Philadelphia translocation t(9:22. [q34; q11.2]) (Full arrow).
Principal causes of Ischemic Priapism.
| Neurological Disorders | Idiopathic Drugs | Idiopathic Drugs (Continuation) | Idiopathic Drugs (Continuation) | Metastatic |
|---|---|---|---|---|
| Syphilis | Papaverine | Penis | ||
| Stroke | Heparin | Clozapine | Prostoglandin E1 | Recto-sigmoid |
| Brain tumors | Warfarin | Diazepam | Sildenafil | Prostate |
| Epilepsy | Testosterone | Kidney | ||
| Intoxication | Dihydralazine | Tamsulosin | ||
| Brain or spinal cord injuries | Labetalol | Doxazosin | Sickle cell anemia | Amyloidosis |
| Lumbar disk herniation or stenosis | Nifedipine | Prazosin | Leukaemia | Fabry’s disease |
| Cauda equine syndrome | Phenoxybenzamine | Multiple myeloma | Diabetes | |
| Regional or general anesthesia | Prazosin | Cocaine | Thalassaemia | Nephrotic syndrome |
| Etanol | Paroxysmal nocturnal haemoglobinuria | Renal failure | ||
| Phenelzine | Marijuana | Thrombocythaemia | Haemodialysis | |
| Trazadone | Henoch-Schonlein purpura |
Therapeutic steps in malignant priapism.
*Oral sympathomimetics, such as etilferine, phenylephrine, metaraminol and terbutaline, are superior to placebo if administered within a short timeframe (<4 h) after onset of priapism. This’s complement treatment while other measures are being.
**Tyrosine kinase inhibitors (TKIs) such as imatinib, dasatinib and nilotinib, are being commenced immediately the diagnosis of CML is confirmed.
***Leukapheresis may be used as a complement to systemic chemotherapy.
WBC: With Blood Cell.
Ten years literature review previous cases with Priapism CML from 2006 to 2016.
| Author(s)/Year | Priapism-CML cases | Age onset | Philadelphia chromosome | Type of priapism | Country |
|---|---|---|---|---|---|
| Pal et al. 2016 [ | 1 | NIA | NIA | LF | India |
| Nerli et al. 2016 [ | 1 | 19 years old | 9:22 translocation | LF | India |
| Alao et al. 2016 [ | 1 | 30 years old | 9:22 translocation | LF | Nigeria |
| Almaeena et al. 2016 [ | 1 | 36 years old | NIA | LF | Saudi Arabia |
| Ergenc et al. 2015 [ | 1 | 18 years old | 9:22 translocation | LF | Turkey |
| Shaeer et al. 2015 [ | 1 | 21 years old | 9:22 translocation | LF | Egypt |
| Villegas et al. 2014 [ | 2 | 24 and 29 years old | Both 9:22 translocation | LF | Spain; Spain |
| Farhan et al. 2014 [ | 1 | 38 years old | 9:22 translocation | LF | Saudi Arabia |
| Magaña et al. 2014 [ | 1 | 32 years old | 9:22 translocation | LF | Mexico |
| Hazra et al. 2013 [ | 1 | 14 years old | NIA | LF | India |
| Veljković et al. 2012 [ | 1 | 16 years old | 9:22 translocation | LF | Serbia |
| Paladino et al. 2011 [ | 1 | 16 years old | NIA | LF | Argentina |
| Tazi. 2009 [ | 1 | 30 years old | Non Karyotype Abnormality | LF | Morocco |
| Jamel et al. 2009 [ | 2 | 21 and 55 years old | Both 9:22 translocation | LF | Pakistan |
| Gupta et al. 2009 [ | 1 | 12 years old | 9:22 translocation | LF | India |
| Htun et al. 2008 [ | 1 | 21 years old | 9:22 translocation | LF | China |
| Ajape et al. 2008 [ | 2 | 30 and 41 years old | Both 9:22 translocation | LF | Nigeria; Nigeria |
| Gupta et al. 2008 [ | 1 | 55 years old | NIA | LF | India |
| Yoshida et al. 2007 [ | 1 | 29 years old | NIA | LF | Japan |
CML: Chronic Myeloid Leukemia; NIA: No Information Available; LF: Low Flow.